comparemela.com

Latest Breaking News On - American society of clinical oncology annual meeting - Page 1 : comparemela.com

Trodelvy Improves Quality of Life Over Chemo in TNBC

Keytruda Plus Chemo May Improve Penile Cancer Outcomes

RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88

YANTAI, China, June 3, 2024 /PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.